镥-177治疗后进展的mCRPC患者接受铽-161 PSMA-617再治疗的疗效与安全性
该研究纳入15例既往接受[177Lu]Lu-PSMA-617治疗后出现生化复发(初始PSA下降≥50%)的mCRPC患者,重新给予[161Tb]Tb-PSMA-617治疗,中位3个周期,平均累计活度19.2±6.4 GBq。生化应答率66.7%(10/15),分子影像应答率86.7%(13/15),中位无进展生存6.4个月,中位总生存15.5个月,未因不良事件停药。
要点
- 既往[177Lu]Lu-PSMA-617治疗获益后进展的mCRPC患者,[161Tb]Tb-PSMA-617再治疗生化应答率66.7%、分子影像应答率86.7%。
- 中位无进展生存6.4个月,中位总生存15.5个月。
- 观察到6例次CTCAE分级恶化(2级至3级或3级至4级),无因不良事件停药。
核心结论
- [161Tb]Tb-PSMA-617作为既往[177Lu]Lu-PSMA-617治疗获益后进展患者的二线RLT,显示出令人鼓舞的应答率、初步临床结局和良好安全性。
研究设计与样本
- 前瞻性注册研究REALITY(NCT04833517)中的探索性评估,纳入15例既往[177Lu]Lu-PSMA-617治疗后生化复发(初始PSA下降≥50%)的mCRPC患者。
- 患者接受[161Tb]Tb-PSMA-617中位3个周期(范围2-7),平均给药活度5.4±1.1 GBq,平均累计活度19.2±6.4 GBq。
- 疗效通过血清PSA和[68Ga]Ga-PSMA-11 PET/CT的总病灶PSMA(TLP)评估,不良事件按CTCAE 5.0版评估。
主要发现
- 生化应答率为66.7%(10/15),分子影像应答率为86.7%(13/15)。
- 自[161Tb]Tb-PSMA-617治疗开始,中位无进展生存为6.4个月,中位总生存为15.5个月。
- 共观察到6例次CTCAE分级恶化(2级至3级或3级至4级),无因不良事件终止PSMA RLT的报道。
关键数值与推荐
- 生化应答定义为血清PSA评估的应答,分子影像应答通过[68Ga]Ga-PSMA-11 PET/CT的TLP评估。
- 不良事件采用CTCAE 5.0版在基线和随访时评估。
临床怎么用
- 对于既往[177Lu]Lu-PSMA-617治疗曾获生化应答后进展的mCRPC患者,可考虑[161Tb]Tb-PSMA-617作为二线RLT选择。
- 治疗期间需按CTCAE 5.0版监测不良事件,本研究中未出现因不良事件停药。
局限性
- 样本量仅15例,为探索性评估,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To enhance the effectiveness of radioligand therapy (RLT), new prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals utilizing alternative radionuclides are under active investigation. One promising alternative to the established 177 Lu is the use of 161 Tb. A key advantage of 161 Tb is its emission of a higher proportion of low-energy conversion and Auger electrons, which may contribute to enhanced therapeutic effectiveness. This study provides a first exploratory evaluation of the efficacy and safety of [ 161 Tb]Tb-PSMA-617 in patients with progression after [ 177 Lu]Lu-PSMA-617, aiming to generate early clinical insights. METHODS: The study included 15 patients with mCRPC, who were enrolled in the "prospective registry to assess outcome and toxicity of targeted radionuclide therapy in patients with mCRPC in clinical routine" (REALITY Study; NCT04833517). All patients had received conventional PSMA RLT using [ 177 Lu]Lu-PSMA-617, which resulted in initial biochemical response (PSA decline ≥50%), followed by a biochemical relapse, prompting the re-initiation of PSMA RLT using [ 161 Tb]Tb-PSMA-617. Patients received a median of 3 (range: 2-7) cycles with mean administered activity of 5.4 ± 1.1 GBq and mean cumulative activity of 19.2 ± 6.4 GBq [ 161 Tb]Tb-PSMA-617. Treatment response was assessed both biochemically by serum PSA levels and through molecular imaging by total lesion PSMA (TLP) on [ 68 Ga]Ga-PSMA-11 PET/CT scans. Adverse events were assessed at baseline and follow-up using the "Common Terminology Criteria for Adverse Events" (Version 5.0). RESULTS: [ 161 Tb]Tb-PSMA-617 RLT showed response rates of 66.7% (10/15 patients) based on biochemical assessment and 86.7% (13/15 patients) based on molecular imaging assessment. Beginning with the initiation of [ 161 Tb]Tb-PSMA-617 RLT, the median progression-free survival (PFS) was 6.4 months, and the median overall survival (OS) was 15.5 months. In total, 6 CTCAE grade deteriorations from grade 2 to grade 3 or from grade 3 to grade 4 were observed. No discontinuation of PSMA RLT due to adverse events was reported. CONCLUSIONS: [ 161 Tb]Tb-PSMA-617 RLT emerges as a promising treatment option, demonstrating encouraging response rates, preliminary clinical outcomes, and a favorable safety profile as second-line RLT in progressing patients who previously benefited from [ 177 Lu]Lu-PSMA-617 RLT.
引用
- Rosar F, Burgard C, Hoang SPT, et al. Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617. Clin Nucl Med. 2026. PMID: 42080618. doi:10.1097/RLU.0000000000006384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。